NL-OMON24345招募中不适用
A Phase I open label/ Phase II randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma.
ovartis Pharma0 个研究点目标入组 130 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 130
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male or female patients ¡Ý 18 years old with ability to take oral drugs;
- •2. Diagnosis of advanced HCC according to the AASLD Guidelines (Bruix and Sherman 2005);
排除标准
- •1. Patients currently receiving any anti cancer therapy or who have received any local anti cancer therapy ¡Ü4 weeks prior to study treatment start;
- •2. Active bleeding during the last 30 days;
研究者
相似试验
尚未招募
不适用
A Phase I open label/ Phase II randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinomaliver cancer10019815Hepatocellular carcinomaNL-OMON32745ovartis15
进行中（未招募）
不适用
A phase 1 open label/phase 2 randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinomaadvanced hepatocellular carcinomaEUCTR2008-004096-21-DEovartis Pharma Services AG130
进行中（未招募）
1 期
A phase 1 open label/phase 2 randomized, double-blind, multicenter study investigating the combination of RAD001 and sorafenib (Nexavar®) in patients with advanced hepatocellular carcinoma - NAadvanced hepatocellular carcinomaEUCTR2008-004096-21-NLovartis Pharma Services AG
进行中（未招募）
1 期
A Study of Soft Tissue Sarcoma with Olaratumab, Gemcitabine and Docetaxelsoft tissue sarcomaMedDRA version: 15.1Level: HLGTClassification code 10041299Term: Soft tissue sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-001316-34-PLEli Lilly and Company310
进行中（未招募）
1 期
A Study of Soft Tissue Sarcoma with Olaratumab, Gemcitabine and DocetaxelEUCTR2015-001316-34-ESilly S.A.310